AGEN
AGENUS INCCompany Information
- Company Name
- AGENUS INC
- CIK
- CIK0001098972
- Category
- Accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- AGEN: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- AGEN
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-02-15
- Last sale
- 2022-01-06
- Shares purchased (TTM)
- 525,000
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 14,267,661
- Shares outstanding
- 41,338,000
- Ownership
- 34.51%
Earnings Market Reaction
- Filing date
- 2026-08-07
- Price on filing date
- —
- 1-month reaction
- 10.06%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 19 | 35 | 3 | 3 | 10 | 18 | 40 | 45 | 94 | 53 | 76 | 106 | ||||||
| Escrow Deposit | 8 | 8 | - | - | - | - | - | - | - | - | - | - | ||||||
| Accounts Receivable Net Current | 15 | 7 | 2 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 26 | 1 | ||||||
| Notes Receivable Net | - | - | 5 | 6 | - | - | - | - | - | - | - | - | ||||||
| Prepaid Expense Current | 3 | 4 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 4 | 8 | 16 | ||||||
| Assets Held For Sale Not Part Of Disposal Group Current | 0 | 0 | 122 | 122 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Current | 2 | 2 | 1 | 1 | 2 | 2 | 2 | 3 | 3 | 3 | 2 | 2 | ||||||
| Assets Current | 79 | 95 | 133 | 134 | 13 | 23 | 46 | 50 | 100 | 60 | 112 | 126 | ||||||
| Property Plant And Equipment Net | 14 | 15 | 15 | 16 | 113 | 117 | 120 | 124 | 128 | 130 | 133 | 140 | ||||||
| Operating Lease Right Of Use Asset | 7 | 7 | 8 | 8 | 26 | 27 | 27 | 29 | 29 | 29 | 30 | 30 | ||||||
| Goodwill | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 25 | 25 | 25 | 25 | 25 | ||||||
| Intangible Assets Net Excluding Goodwill | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 4 | ||||||
| Equity Method Investments | 25 | 23 | 24 | 30 | - | - | 0 | - | - | - | - | - | ||||||
| Other Assets Noncurrent | 4 | 3 | 3 | 3 | 5 | 6 | 6 | 7 | 7 | 8 | 9 | 11 | ||||||
| Assets | 173 | 186 | 227 | 234 | 185 | 200 | 226 | 238 | 292 | 257 | 314 | 335 | ||||||
Liabilities And Stockholders Equity | ||||||||||||||||||
| Long Term Debt Current | 30 | 30 | 45 | 11 | 11 | 1 | 3 | 13 | 13 | 14 | 0 | 0 | ||||||
| Contract With Customer Liability Current | - | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 5 | ||||||
| Operating Lease Liability Current | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 2 | 3 | 3 | 3 | ||||||
| Accounts Payable Current | 59 | 71 | 83 | 85 | 74 | 64 | 61 | 46 | 51 | 51 | 61 | 41 | ||||||
| Accrued Liabilities Current | 28 | 37 | 34 | 32 | 39 | 36 | 35 | 37 | 41 | 41 | 45 | 38 | ||||||
| Other Liabilities Current | 0 | 1 | 1 | 1 | 4 | 5 | 8 | 13 | 16 | 14 | 14 | 13 | ||||||
| Liabilities Current | 232 | 249 | 323 | 287 | 235 | 208 | 221 | 271 | 271 | 256 | 256 | 198 | ||||||
| Long Term Debt Noncurrent | - | - | 0 | 24 | 23 | 33 | 30 | 0 | 0 | 0 | 13 | 13 | ||||||
| Contract With Customer Liability Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | ||||||
| Operating Lease Liability Noncurrent | 10 | 10 | 10 | 10 | 53 | 54 | 55 | 55 | 56 | 62 | 63 | 63 | ||||||
| Other Liabilities Noncurrent | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 3 | 5 | 8 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4 | ||||||
| Additional Paid In Capital | 1,945 | 1,922 | 1,912 | 1,899 | 1,883 | 1,868 | 1,858 | 1,846 | 1,830 | 1,817 | 1,796 | 1,777 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | -0 | -2 | -2 | -1 | -1 | -1 | -1 | -1 | -1 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -2,144 | -2,144 | -2,183 | -2,172 | -2,236 | -2,208 | -2,183 | -2,137 | -2,071 | -2,018 | -1,956 | -1,909 | ||||||
| Stockholders Equity | -206 | -228 | -278 | -281 | -355 | -322 | -326 | -272 | -241 | -201 | -160 | -115 | ||||||
| Minority Interest | -7 | -7 | -7 | -7 | 18 | 19 | 20 | 21 | 20 | 11 | 12 | 14 | ||||||
| Liabilities And Stockholders Equity | 173 | 186 | 227 | 234 | 185 | 200 | 226 | 238 | 292 | 257 | 314 | 335 | ||||||
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 48 | 48 | 47 | 47 | 75 | 76 | 73 | 71 | 68 | 65 | 62 | 61 | ||||||
| Finite Lived Intangible Assets Accumulated Amortization | 17 | 17 | 17 | 17 | 17 | 17 | 17 | 18 | 18 | 18 | 18 | 17 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | - | - | - | 0.01 | - | - | - | 0.01 | - | ||||||
| Preferred Stock Shares Authorized | 5 | 5 | 5 | - | - | - | 5 | - | - | - | 5 | - | ||||||
| Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | ||||||
| Common Stock Shares Authorized | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | ||||||
| Common Stock Shares Issued | 43 | 39 | 35 | 33 | 30 | 27 | 24 | 22 | 21 | 21 | 20 | 381 | ||||||
| Shares Outstanding | 43 | 39 | 35 | 33 | 30 | 27 | 24 | 22 | 21 | 21 | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAGENUS INC (AGEN) — SEC Financial Statements & Analysis
AGENUS INC (AGEN) is a biological products, (no diagnostic substances) company, incorporated in DE. AGENUS INC trades on Nasdaq as: AGEN. AGENUS INC (AGEN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, AGENUS INC carries a market cap of $126.49M, a P/E ratio of 1.36x, a P/B ratio of -0.61x, a P/S ratio of 0.95x, an enterprise value of $137.82M, and an EV/EBITDA multiple of 3.37x. On profitability, it posts a gross margin of 101.07%, an operating margin of 27.28%, a net margin of 70.00%, a Return on Equity (ROE) of -33.15%, and a Return on Assets (ROA) of 51.90%. Per share, it reports EPS of $2.25, diluted EPS of $2.25, free cash flow per share of $-2.38, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 30.47% year-over-year, net income growth of -156.22% year-over-year, and EPS growth of -138.24% year-over-year. On the balance sheet, it maintains a current ratio of 0.34x, a quick ratio of 0.33x, working capital of $-153.01M, a debt-to-equity ratio of -1.13x, a debt ratio of 1.34, an interest coverage ratio of 0.61x, free cash flow of $-98.50M (TTM), and net debt of $11.33M. Figures sourced from SEC EDGAR.
- Market Cap
- $126.49M
- P/E TTM
- 1.36x
- EPS TTM
- $2.25
- P/B TTM
- -0.61x
- ROE TTM
- -33.15%
- ROA TTM
- 51.90%
- Debt To Equity
- -1.13x
- Free Cash Flow TTM
- $-98.50M
- Net Revenue TTM Growth 1Y
- 30.47%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is AGENUS INC in?
AGENUS INC (AGEN) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does AGEN trade on?
AGENUS INC (AGEN) trades on the Nasdaq.
Where is AGENUS INC incorporated?
AGENUS INC is incorporated in DE.
When was AGENUS INC (AGEN)'s most recent SEC filing?
AGENUS INC (AGEN)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07.
What is AGEN's market cap?
AGENUS INC (AGEN) has a market capitalization of $126.49M as of 2026-06-30.
What is AGEN's P/E ratio?
AGENUS INC (AGEN)'s trailing twelve month P/E ratio is 1.36x as of 2026-06-30.
What is AGEN's EPS (earnings per share)?
AGENUS INC (AGEN)'s trailing twelve month EPS is $2.25 as of 2026-06-30.
What is AGEN's ROE (return on equity)?
AGENUS INC (AGEN)'s trailing twelve month Return on Equity (ROE) is -33.15% as of 2026-06-30.
What is AGEN's ROA (return on assets)?
AGENUS INC (AGEN)'s trailing twelve month Return on Assets (ROA) is 51.90% as of 2026-06-30.
What is AGEN's EV/EBITDA?
AGENUS INC (AGEN)'s trailing twelve month EV/EBITDA is 3.37x as of 2026-06-30.